These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12789387)

  • 41. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy.
    Gontero P; Fontana F; Zitella A; Montorsi F; Frea B
    BJU Int; 2005 Feb; 95(3):359-65. PubMed ID: 15679794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine.
    Viswaroop B; B A; Gopalakrishnan G
    Natl Med J India; 2005; 18(6):299-301. PubMed ID: 16483029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of intracavernosal alprostadil in erectile dysfunction.
    Gingell C
    Hosp Med; 1998 Oct; 59(10):777. PubMed ID: 9850293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intracavernosal injections and fibrosis: myth or reality?
    Tal R; Mulhall JP
    BJU Int; 2008 Aug; 102(5):525-6. PubMed ID: 18485038
    [No Abstract]   [Full Text] [Related]  

  • 45. Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan).
    Usta MF; Sanabria J; Bivalacqua TJ; Hellstrom WJ
    Int J Impot Res; 2004 Feb; 16(1):73-7. PubMed ID: 14963475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis.
    Raina R; Lakin MM; Thukral M; Agarwal A; Ausmundson S; Montague DK; Klein E; Zippe CD
    Int J Impot Res; 2003 Oct; 15(5):318-22. PubMed ID: 14562131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-injection devices for intracavernosal pharmacotherapy: operational classification and safety considerations.
    Pescatori ES; Calpista A; Artibani W; Pagano F; Calabro A
    Int J Impot Res; 1996 Jun; 8(2):53-7; discussion 57-8. PubMed ID: 8858390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the alleviative action of neurotropin for penile pain associated with intracavernous injection of prostaglandin E1 assessed using the visual analogue scale.
    Sato Y; Suzuki N; Adachi H; Hisasue S; Horita H; Tsukamoto T
    Int J Impot Res; 1998 Mar; 10(1):1-3. PubMed ID: 9542683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implantation of penile prosthesis in a patient with severe corporeal fibrosis induced by cavernosal injection therapy.
    Park JK; Kim HJ; Kang MH; Jeong YB
    Int J Impot Res; 2002 Dec; 14(6):545-6. PubMed ID: 12494294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostaglandin E1 diluted solution: preparation technique and stability evaluation.
    Fraccaro A; Grion AM; Gaion RM; Ricatti MG; Pescatori ES; Calabrò A
    Int J Impot Res; 1993 Mar; 5(1):43-5. PubMed ID: 8348212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on oral treatments for male erectile dysfunction.
    Kalsi JS; Kell PD
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):267-74. PubMed ID: 15096134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis.
    Raina R; Agarwal A; Zaramo CE; Ausmundson S; Mansour D; Zippe CD
    Int J Impot Res; 2005; 17(1):86-90. PubMed ID: 15526008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracavernosal injection therapy and surgical therapy in diabetic patients with erectile dysfunction.
    Savoca G; Silvestre G; Belgrano E
    Diabetes Nutr Metab; 2002 Feb; 15(1):53-7. PubMed ID: 11942740
    [No Abstract]   [Full Text] [Related]  

  • 54. Peyronie's disease: a silent consequence of diabetes mellitus.
    Tefekli A; Kandirali E; Erol B; Tunc M; Kadioglu A
    Asian J Androl; 2006 Jan; 8(1):75-9. PubMed ID: 16372122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intracavernosal injection algorithm.
    Albaugh JA
    Urol Nurs; 2006 Dec; 26(6):449-53. PubMed ID: 17253079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.
    Shah PJ; Dinsmore W; Oakes RA; Hackett G
    Curr Med Res Opin; 2007 Oct; 23(10):2577-83. PubMed ID: 17875241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales.
    Jiann BP; Yu CC; Su CC
    Int J Impot Res; 2004 Dec; 16(6):527-30. PubMed ID: 15229626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral midodrine for prostaglandin e1 induced priapism in spinal cord injured patients.
    Soler JM; Previnaire JG; Mieusset R; Plante P
    J Urol; 2009 Sep; 182(3):1096-100. PubMed ID: 19616810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The impact of creating andrology units on the treatment of erectile dysfunction with intracavernosal injections].
    Ramada Benlloch FJ; Navalon Verdejo P; Claramonte Ramon FJ; Beltrán Mesenguer JF; Ramos de Campos M; Zaragozá Orts J
    Arch Esp Urol; 1999 Apr; 52(3):257-61. PubMed ID: 10371742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus.
    Israilov S; Shmuely J; Niv E; Engelstein D; Livne P; Boniel J
    Int J Impot Res; 2005; 17(5):431-6. PubMed ID: 15889124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.